Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Screening assays

A measurement method and selected technology, applied in the field of RNA biology, capable of solving problems such as complex calculations

Inactive Publication Date: 2007-02-21
NOVARTIS AG
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0010] If the secondary structure motif of interest can be formed several times within a structure, then p * The calculation will be more complicated

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Screening assays
  • Screening assays
  • Screening assays

Examples

Experimental program
Comparison scheme
Effect test

Embodiment

[0171] Embodiment A-experimental scheme:

[0172] a) Preparation of fluorescently labeled RNA. Using 5'O-dimethoxytrityl-2'O-triisopropoxymethyl-protected β'-cyanoethyl-(N,N-diisopropyl-)nucleotide Phosphoramides (GlenResearch), using published methods (see for example Chaix C. et al., Nucleic Acids Symp. Ser. 1989, (21): 45-6; Scaringe S.A. et al., Nucleic Acids Res. 1990, 18(18) : 5433-41) and the manufacturer's instructions, the 5' amino-C6 modified RNA was synthesized on a 394A synthesizer (Applied Biosystems). ORN was cleaved from the support, base-, phosphate- and 2'-deprotected, and purified by denaturing polyacrylamide gel electrophoresis according to standard methods. RNA concentration was calculated using UV-absorbance at 260 nm according to the Bouguer-Lambert-Beer Law; where used according to reference (Gray D.M. et al., Methods in Enzymology 1995, 246: 19-34) Determine the exact molar extinction coefficient at 260 nm. According to analytical RP-HPLC analysis (...

Embodiment B

[0189] Example B: Calculation method

[0190] Calculation of RNA accessibility P* using a constrained partition function M . Here we describe the P* of the secondary structure elements M For calculations of , the secondary structure elements are defined by sequence patterns with secondary structure constraints, such as NNUUNNUUU in a fully single-stranded conformation. P* M can be directly calculated as in equation [III] with respect to the setting of P*. In order to avoid numerical errors, P(α) is not calculated as a fraction of the partition function, but due to the difference in ensemble free energy, P(α)=exp((W-W α ) / RT), where W is the ensemble free energy of the RNA sequence, W αis the ensemble free energy of a structurally constrained thermodynamic secondary structure ensemble, where all sites in α form specific secondary structure elements. Ensemble free energy can be calculated using standard RNA secondary structure prediction software (Zuker M. Curr. Opin. Stru...

Embodiment 1

[0196] Example 1: Manipulation of HuR association with IL-2 mRNA, thereby manipulating IL-2 mRNA stability

[0197] Construction of opener, closer and negative control ORNs targeting IL-2 and TNF-α mRNA; experimentally validated in vitro and in human primary cell lysates.

[0198] figure 2 Plots are presented showing the effect of hybridization of 20mer ORNs on the fraction of accessible RNA structures calculated for the purpose of designing openers and negative control ORNs directed against IL-2. Apparently, the dramatic increase in accessibility is restricted to a limited number of "hotspots" within the mRNA, mostly located externally and not near the HuR binding site. At many other positions, hybridization leaves the local ARE conformation barely affected. From these hotspots, 4 possible opener ORNs and 2 negative control ORNs were selected for experimental characterization (Table 1). In the first step, we used ss ORN.

[0199] Opener roles were initially identified in...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention provides a method for modulating regulatory RNA-ligand binding, assays for identifying agents and oligonucleotides that change the thermodynamic probability of a secondary structure element of an RNA molecule.

Description

technical field [0001] The present invention provides a method for modulating regulatory RNA-ligand interactions, such as identification, selection and validation of opener and closer nucleic acids for controllable manipulation of RNA secondary structure. In a preferred embodiment, the openers or closers of the invention are used to modulate RNA-ligand interactions and associated downstream processes, such as gene expression, that are dependent on RNA secondary structure. [0002] The present invention relates, for example, to the field of RNA biology, in particular to the analysis and prediction of RNA secondary structures, and to RNA-ligand interactions dependent on RNA secondary structures. In particular, the present invention relates to protein-RNA interactions involved in gene regulation, more particularly protein-RNA interactions involved in post-transcriptional regulation of gene expression, especially the control of mRNA stability, for example through the protein HuR( ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C12N15/11C12Q1/68C12N15/113C12N15/115
CPCC12N15/115C12N2320/10C12N15/1136C12N15/111C12N2310/11A61P29/00A61P31/00A61P31/12A61P35/00A61P37/08A61P43/00A61P9/00C12N15/10C12N15/11C12Q1/6813
Inventor M·奥尔J·哈克米勒M·雅里茨N-C·梅斯纳
Owner NOVARTIS AG
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com